Chronic Myeloid Leukemia
268
29
45
135
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
43 trials with published results (16%)
Research Maturity
135 completed trials (50% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.1%
27 terminated out of 268 trials
83.3%
-3.2% vs benchmark
10%
28 trials in Phase 3/4
32%
43 of 135 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 135 completed trials
Clinical Trials (268)
A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System